<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00313911</url>
  </required_header>
  <id_info>
    <org_study_id>A3L04</org_study_id>
    <nct_id>NCT00313911</nct_id>
  </id_info>
  <brief_title>Safety of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Tritanrix-HepB/Hib™ and OPV Given at Age 2, 4, and 6 Months.</brief_title>
  <official_title>Large Scale Safety Study of a DTaP-IPV-Hep B-PRP~T Combined Vaccine, in Comparison to Tritanrix-Hep B/Hib™ and OPV Administered at 2, 4, and 6 Months of Age in Latin American Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate that DTaP-IPV-HB-PRP~T combined vaccine does not induce a higher incidence
      rate of high fever than Tritanrix-HepB/Hib™ and Oral Polio Vaccine (OPV) after any of the
      three vaccinations at 2, 4, and 6 months of age for each subject.

      To evaluate the overall safety in terms of:

      Any solicited adverse reactions in the first 7 days after each injection, Any adverse events
      and reactions in the first 30 days after each injection, Any serious adverse events during
      the trial.

      Immunogenicity:

      To document the immune response to Hepatitis B antigen of the three batches of the
      investigational DTaP-IPV-HB-PRP~T vaccine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With High Fever Observed After Either DTaP-IPV-Hep B-PRP~T or Tritanrix Hep B/Hib™ + Placebo or Tritanrix-Hep B/Hib™ + Placebo Injection.</measure>
    <time_frame>Day 0 up to Day 7 post-injection</time_frame>
    <description>High fever was defined as rectal temperature equivalent to ≥ 39.6ºC.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers of Anti Hepatitis B Antibodies Following Vaccination With Either DTaP-IPV-Hep B-PRP~T Vaccine + Placebo or Tritanrix-Hep B/Hib™ + Placebo</measure>
    <time_frame>Day 30 post-dose 3</time_frame>
    <description>Anti-hepatitis B (Hep B) antibodies were measured by automated enhanced chemiluminescence assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Reaching Seroprotection Threshold Following Vaccination With Either DTaP-IPV-Hep B-PRP~T Vaccine + Placebo or Tritanrix-Hep B/Hib™ + Placebo</measure>
    <time_frame>Day 30 post-dose 3</time_frame>
    <description>Anti hepatitis B (Hep B) antibodies were measured by automated enhanced chemiluminescence assay.
Two Seroprotection thresholds were defined: a titer ≥ 10 mIU/mL and ≥ 100 mIU/mL, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting at Least One Solicited Injection Site or Systemic Reaction Following Each Vaccination</measure>
    <time_frame>Day 0 up to Day 7 Post-injection</time_frame>
    <description>Solicited Injection Site Reactions: Pain, Erythema, Swelling. Solicited Systemic Reactions: Pyrexia (Temperature), Vomiting, Crying, Somnolence, Anorexia, Irritability.
Severe solicited reactions were defined as follows: Pain, cries when injected limb is moved or the movement of the injected limb is reduced; Erythema and Swelling, ≥5 cm; Fever ≥39.6 ºC; Vomiting, ≥6 episodes per 24 hours or requiring parenteral hydration; Crying, &gt;3 hours; Somnolence, sleeping most of the time or difficulty to wake up; Anorexia, refuses ≥3 feeds or refuses most feeds; Irritability, inconsolable.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2133</enrollment>
  <condition>Diphtheria</condition>
  <condition>Tetanus</condition>
  <condition>Pertussis</condition>
  <condition>Haemophilus Influenzae Type b</condition>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Group 1: DTaP-IPV-Hep B-PRP-T</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Tritanrix-Hep B/Hib™+OPV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DTaP-IPV-HB-PRP~T</intervention_name>
    <description>0.5 mL, Intramuscular (IM)</description>
    <arm_group_label>Group 1: DTaP-IPV-Hep B-PRP-T</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tritanrix-HepB/Hib</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>Group 2: Tritanrix-Hep B/Hib™+OPV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  2 months old infants on the day of inclusion

          -  Born at full term of pregnancy (≥ 37 weeks) with a birth weight ≥ 2.5 kg

          -  Informed consent form signed by one or both parents or by the legally acceptable
             representative and 1 or 2 independent witnesses

          -  Able to attend all scheduled visits and to comply with all trial procedures

          -  Has complied with the national immunization calendar (BCG for both countries) for the
             first 2 months of life.

        Exclusion Criteria:

          -  Participation in another clinical trial in the 4 weeks preceding the first trial
             vaccination

          -  Planned participation in another clinical trial during the present trial period

          -  Congenital or acquired immunodeficiency, immunosuppressive therapy such as long-term
             systemic corticosteroids therapy

          -  Subjects with congenital or acquired immunodeficiency in the child's surrounding

          -  Systemic hypersensitivity to any of the vaccine components or history of a
             life-threatening reaction to the trial vaccine or a vaccine containing the same
             substances

          -  Chronic illness at a stage that could interfere with trial conduct or completion

          -  Blood or blood-derived products received since birth

          -  Any vaccination in the 4 weeks preceding the first trial vaccination

          -  Vaccination planned in the 4 weeks following the trial vaccination

          -  Documented history of pertussis, tetanus, diphtheria, poliomyelitis, Haemophilus
             influenzae type b or hepatitis B infection(s) (confirmed either clinically,
             serologically or microbiologically)

          -  Mother known as seropositive for HIV or Hepatitis C, or known carrier of Hepatitis B
             surface antigen

          -  Previous vaccination against pertussis, tetanus, diphtheria, poliomyelitis, or
             Haemophilus influenzae type b infection(s)

          -  Coagulopathy, thrombocytopenia or a bleeding disorder contraindicating IM vaccination

          -  History of seizures

          -  Febrile or acute illness on the day of inclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Days</minimum_age>
    <maximum_age>71 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Mexico DF</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
    <country>Peru</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
  </link>
  <link>
    <url>http://www.sanofi.com</url>
  </link>
  <results_reference>
    <citation>Macías M, Lanata CF, Zambrano B, Gil AI, Amemiya I, Mispireta M, Ecker L, Santos-Lima E. Safety and immunogenicity of an investigational fully liquid hexavalent DTaP-IPV-Hep B-PRP-T vaccine at two, four and six months of age compared with licensed vaccines in Latin America. Pediatr Infect Dis J. 2012 Aug;31(8):e126-32. doi: 10.1097/INF.0b013e318258400d.</citation>
    <PMID>22531237</PMID>
  </results_reference>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2006</study_first_submitted>
  <study_first_submitted_qc>April 11, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2006</study_first_posted>
  <results_first_submitted>September 18, 2012</results_first_submitted>
  <results_first_submitted_qc>October 18, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 19, 2012</results_first_posted>
  <last_update_submitted>April 2, 2014</last_update_submitted>
  <last_update_submitted_qc>April 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diphtheria</keyword>
  <keyword>Tetanus</keyword>
  <keyword>Pertussis</keyword>
  <keyword>Recombinant Hepatitis B</keyword>
  <keyword>Poliomyelitis</keyword>
  <keyword>Haemophilus influenzae type b</keyword>
  <keyword>Tetanus protein</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Whooping Cough</mesh_term>
    <mesh_term>Tetanus</mesh_term>
    <mesh_term>Diphtheria</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled and treated from 17 July 2006 to 02 January 2008 in 1 clinical center in Mexico and 1 clinical center in Peru.</recruitment_details>
      <pre_assignment_details>A total of 2133 participants who met the inclusion and exclusion criteria were enrolled and vaccinated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>DTaP-IPV-Hep B-PRP~T</title>
          <description>Participants received Diphtheria (D), tetanus (T), pertussis (acellular, component) (aP), hepatitis B (hep B [recombinant DNA]) and poliomyelitis (Inactivated [IPV]), and Haemophilus influenzae type b (Hib) conjugated vaccine adsorbed (DTaP-IPV-Hep B-PRP~T) plus a Placebo, oral poliovirus vaccine (OPV) in a 3-dose series with single doses at 2, 4, and 6 months of age.</description>
        </group>
        <group group_id="P2">
          <title>Tritanrix-Hep B/Hib™ + OPV</title>
          <description>Participants received Tritanrix-Hep B/Hib™ + oral poliovirus vaccine (OPV) in a 3-dose series with single doses at 2, 4, and 6 months of age.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1422">N for outcomes adjusted to include participant in Group 2 that got vaccine assigned to this group.</participants>
                <participants group_id="P2" count="711">A participant in this group mistakenly got Group 1 vaccine. N in outcomes adjusted accordingly.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1328"/>
                <participants group_id="P2" count="670"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="94"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Serious adverse event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not meet age criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>DTaP-IPV-Hep B-PRP~T</title>
          <description>Participants received Diphtheria (D), tetanus (T), pertussis (acellular, component) (aP), hepatitis B (hep B [recombinant DNA]) and poliomyelitis (Inactivated [IPV]), and Haemophilus influenzae type b (Hib) conjugated vaccine adsorbed (DTaP-IPV-Hep B-PRP~T) plus a Placebo, oral poliovirus vaccine (OPV) in a 3-dose series with single doses at 2, 4, and 6 months of age.</description>
        </group>
        <group group_id="B2">
          <title>Tritanrix-Hep B/Hib™ + OPV</title>
          <description>Participants received Tritanrix-Hep B/Hib™ + oral poliovirus vaccine (OPV) in a 3-dose series with single doses at 2, 4, and 6 months of age.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1422"/>
            <count group_id="B2" value="711"/>
            <count group_id="B3" value="2133"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1422"/>
                    <measurement group_id="B2" value="711"/>
                    <measurement group_id="B3" value="2133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Age Continuous</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.89" spread="0.195"/>
                    <measurement group_id="B2" value="1.88" spread="0.197"/>
                    <measurement group_id="B3" value="1.88" spread="0.196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="706"/>
                    <measurement group_id="B2" value="344"/>
                    <measurement group_id="B3" value="1050"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="716"/>
                    <measurement group_id="B2" value="367"/>
                    <measurement group_id="B3" value="1083"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="712"/>
                    <measurement group_id="B2" value="355"/>
                    <measurement group_id="B3" value="1067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peru</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="710"/>
                    <measurement group_id="B2" value="356"/>
                    <measurement group_id="B3" value="1066"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With High Fever Observed After Either DTaP-IPV-Hep B-PRP~T or Tritanrix Hep B/Hib™ + Placebo or Tritanrix-Hep B/Hib™ + Placebo Injection.</title>
        <description>High fever was defined as rectal temperature equivalent to ≥ 39.6ºC.</description>
        <time_frame>Day 0 up to Day 7 post-injection</time_frame>
        <population>The occurrence of high fever was assessed for all enrolled and vaccinated participants, intent-to-treat (safety) population. Total numbers of participants in each group adjusted for the participant that got a vaccine assigned for the other group.</population>
        <group_list>
          <group group_id="O1">
            <title>DTaP-IPV-Hep B-PRP~T</title>
            <description>Participants received Diphtheria (D), tetanus (T), pertussis (acellular, component) (aP), hepatitis B (hep B [recombinant DNA]) and poliomyelitis (Inactivated [IPV]), and Haemophilus influenzae type b (Hib) conjugated vaccine adsorbed (DTaP-IPV-Hep B-PRP~T) plus a Placebo, oral poliovirus vaccine (OPV) in a 3-dose series with single doses at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Tritanrix-Hep B/Hib™ + OPV</title>
            <description>Participants received Tritanrix-Hep B/Hib™ + oral poliovirus vaccine (OPV) in a 3-dose series with single doses at 2, 4, and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With High Fever Observed After Either DTaP-IPV-Hep B-PRP~T or Tritanrix Hep B/Hib™ + Placebo or Tritanrix-Hep B/Hib™ + Placebo Injection.</title>
          <description>High fever was defined as rectal temperature equivalent to ≥ 39.6ºC.</description>
          <population>The occurrence of high fever was assessed for all enrolled and vaccinated participants, intent-to-treat (safety) population. Total numbers of participants in each group adjusted for the participant that got a vaccine assigned for the other group.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1423"/>
                <count group_id="O2" value="710"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Post Any Dose (N = 1411, 703)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="39" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Dose 1 (N = 1408, 703)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Dose 2 (N = 1348, 681)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="15" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Dose 3 (N = 1328, 672)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="23" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers of Anti Hepatitis B Antibodies Following Vaccination With Either DTaP-IPV-Hep B-PRP~T Vaccine + Placebo or Tritanrix-Hep B/Hib™ + Placebo</title>
        <description>Anti-hepatitis B (Hep B) antibodies were measured by automated enhanced chemiluminescence assay.</description>
        <time_frame>Day 30 post-dose 3</time_frame>
        <population>Anti-hepatitis B antibody titers were assessed in a subset of the enrolled and vaccinated participants, intent-to-treat population.</population>
        <group_list>
          <group group_id="O1">
            <title>DTaP-IPV-Hep B-PRP~T</title>
            <description>Participants received Diphtheria (D), tetanus (T), pertussis (acellular, component) (aP), hepatitis B (hep B [recombinant DNA]) and poliomyelitis (Inactivated [IPV]), and Haemophilus influenzae type b (Hib) conjugated vaccine adsorbed (DTaP-IPV-Hep B-PRP~T) plus a Placebo, oral poliovirus vaccine (OPV) in a 3-dose series with single doses at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Tritanrix-Hep B/Hib™ + OPV</title>
            <description>Participants received Tritanrix-Hep B/Hib™ + oral poliovirus vaccine (OPV) in a 3-dose series with single doses at 2, 4, and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers of Anti Hepatitis B Antibodies Following Vaccination With Either DTaP-IPV-Hep B-PRP~T Vaccine + Placebo or Tritanrix-Hep B/Hib™ + Placebo</title>
          <description>Anti-hepatitis B (Hep B) antibodies were measured by automated enhanced chemiluminescence assay.</description>
          <population>Anti-hepatitis B antibody titers were assessed in a subset of the enrolled and vaccinated participants, intent-to-treat population.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1075" lower_limit="891" upper_limit="1298"/>
                    <measurement group_id="O2" value="3376" lower_limit="2672" upper_limit="4338"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Reaching Seroprotection Threshold Following Vaccination With Either DTaP-IPV-Hep B-PRP~T Vaccine + Placebo or Tritanrix-Hep B/Hib™ + Placebo</title>
        <description>Anti hepatitis B (Hep B) antibodies were measured by automated enhanced chemiluminescence assay.
Two Seroprotection thresholds were defined: a titer ≥ 10 mIU/mL and ≥ 100 mIU/mL, respectively.</description>
        <time_frame>Day 30 post-dose 3</time_frame>
        <population>Anti-hepatitis B antibody titers were assessed in a subset of the enrolled and vaccinated participants, intent-to-treat population.</population>
        <group_list>
          <group group_id="O1">
            <title>DTaP-IPV-Hep B-PRP~T</title>
            <description>Participants received Diphtheria (D), tetanus (T), pertussis (acellular, component) (aP), hepatitis B (hep B [recombinant DNA]) and poliomyelitis (Inactivated [IPV]), and Haemophilus influenzae type b (Hib) conjugated vaccine adsorbed (DTaP-IPV-Hep B-PRP~T) plus a Placebo, oral poliovirus vaccine (OPV) in a 3-dose series with single doses at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Tritanrix-Hep B/Hib™ + OPV</title>
            <description>Participants received Tritanrix-Hep B/Hib™ + oral poliovirus vaccine (OPV) in a 3-dose series with single doses at 2, 4, and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reaching Seroprotection Threshold Following Vaccination With Either DTaP-IPV-Hep B-PRP~T Vaccine + Placebo or Tritanrix-Hep B/Hib™ + Placebo</title>
          <description>Anti hepatitis B (Hep B) antibodies were measured by automated enhanced chemiluminescence assay.
Two Seroprotection thresholds were defined: a titer ≥ 10 mIU/mL and ≥ 100 mIU/mL, respectively.</description>
          <population>Anti-hepatitis B antibody titers were assessed in a subset of the enrolled and vaccinated participants, intent-to-treat population.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>≥ 10 mIU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 100 mIU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="99" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting at Least One Solicited Injection Site or Systemic Reaction Following Each Vaccination</title>
        <description>Solicited Injection Site Reactions: Pain, Erythema, Swelling. Solicited Systemic Reactions: Pyrexia (Temperature), Vomiting, Crying, Somnolence, Anorexia, Irritability.
Severe solicited reactions were defined as follows: Pain, cries when injected limb is moved or the movement of the injected limb is reduced; Erythema and Swelling, ≥5 cm; Fever ≥39.6 ºC; Vomiting, ≥6 episodes per 24 hours or requiring parenteral hydration; Crying, &gt;3 hours; Somnolence, sleeping most of the time or difficulty to wake up; Anorexia, refuses ≥3 feeds or refuses most feeds; Irritability, inconsolable.</description>
        <time_frame>Day 0 up to Day 7 Post-injection</time_frame>
        <population>Solicited injection site and systemic reactions were assessed in the enrolled and vaccinated participants, intent-to-treat (safety) population. Total numbers of participants (N) in each group adjusted for the participant that got a vaccine assigned for the other group.</population>
        <group_list>
          <group group_id="O1">
            <title>DTaP-IPV-Hep B-PRP~T</title>
            <description>Participants received Diphtheria (D), tetanus (T), pertussis (acellular, component) (aP), hepatitis B (hep B [recombinant DNA]) and poliomyelitis (Inactivated [IPV]), and Haemophilus influenzae type b (Hib) conjugated vaccine adsorbed (DTaP-IPV-Hep B-PRP~T) plus a Placebo, oral poliovirus vaccine (OPV) in a 3-dose series with single doses at 2, 4, and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Tritanrix-Hep B/Hib™ + OPV</title>
            <description>Participants received Tritanrix-Hep B/Hib™ + oral poliovirus vaccine (OPV) in a 3-dose series with single doses at 2, 4, and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting at Least One Solicited Injection Site or Systemic Reaction Following Each Vaccination</title>
          <description>Solicited Injection Site Reactions: Pain, Erythema, Swelling. Solicited Systemic Reactions: Pyrexia (Temperature), Vomiting, Crying, Somnolence, Anorexia, Irritability.
Severe solicited reactions were defined as follows: Pain, cries when injected limb is moved or the movement of the injected limb is reduced; Erythema and Swelling, ≥5 cm; Fever ≥39.6 ºC; Vomiting, ≥6 episodes per 24 hours or requiring parenteral hydration; Crying, &gt;3 hours; Somnolence, sleeping most of the time or difficulty to wake up; Anorexia, refuses ≥3 feeds or refuses most feeds; Irritability, inconsolable.</description>
          <population>Solicited injection site and systemic reactions were assessed in the enrolled and vaccinated participants, intent-to-treat (safety) population. Total numbers of participants (N) in each group adjusted for the participant that got a vaccine assigned for the other group.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1423"/>
                <count group_id="O2" value="710"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Pain Post Dose 1 (N=1410, 703)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="831"/>
                    <measurement group_id="O2" value="574" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe Pain Post Dose 1 (N=1408, 703)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="175"/>
                    <measurement group_id="O2" value="193" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Pain Post Dose 2 (N=1348, 681)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="744"/>
                    <measurement group_id="O2" value="506" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe Pain Post Dose 2 (N=1348, 681)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="95" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Pain Post Dose 3 (N=1327, 672)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="519"/>
                    <measurement group_id="O2" value="448" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe Pain Post Dose 3 (N=1327, 672)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="65" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Erythema Post Dose 1 (N=1408, 703)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                    <measurement group_id="O2" value="234" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe Erythema Post Dose 1 (N=1408, 703)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="15" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Erythema Post Dose 2 (N=1348, 681)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="427"/>
                    <measurement group_id="O2" value="308" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe Erythema Post Dose 2 (N=1348, 681)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="16" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Erythema Post Dose 3 (N=1327, 672)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="587"/>
                    <measurement group_id="O2" value="340" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe Erythema Post Dose 3 (N=1327, 672)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="12" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling Post Dose 1 (N=1406, 703)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151"/>
                    <measurement group_id="O2" value="188" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe Swelling Post Dose 1 (N=1406, 703)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="24" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling Post Dose 2 (N=1348, 681)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="259"/>
                    <measurement group_id="O2" value="270" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe Swelling Post Dose 2 (N=1348, 681)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="11" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling Post Dose 3 (N=1327, 672)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="400"/>
                    <measurement group_id="O2" value="323" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe Swelling Post Dose 3 (N=1327, 672)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Pyrexia Post Dose 1 (N=1408, 703)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="538"/>
                    <measurement group_id="O2" value="473" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe Pyrexia Post Dose 1 (N=1408, 703)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Pyrexia Post Dose 2 (N=1348, 681)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="675"/>
                    <measurement group_id="O2" value="457" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe Pyrexia Post Dose 2 (N=1348, 681)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="16" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Pyrexia Post Dose 3 (N=1328, 672)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="552"/>
                    <measurement group_id="O2" value="445" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe Pyrexia Post Dose 3 (N=1328, 672)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="23" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Vomiting Post Dose 1 (N=1408, 703)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="230"/>
                    <measurement group_id="O2" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe Vomiting Post Dose 1 (N=1408, 703)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="4" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Vomiting Post Dose 2 (N=1348, 681)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="152"/>
                    <measurement group_id="O2" value="75" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe Vomiting Post Dose 2 (N=1348, 681)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Vomiting Post Dose 3 (N=1328, 672)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="167"/>
                    <measurement group_id="O2" value="95" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe Vomiting Post Dose 3 (N=1328, 672)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="10" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Crying Post Dose 1 (N=1409, 703)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="800"/>
                    <measurement group_id="O2" value="564" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe Crying Post Dose 1 (N=1409, 703)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="26" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Crying Post Dose 2 (N=1348, 681)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="721"/>
                    <measurement group_id="O2" value="481" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe Crying Post Dose 2 (N=1348, 681)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Crying Post Dose 3 (N=1327, 672)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="466"/>
                    <measurement group_id="O2" value="391" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe Crying Post Dose 3 (N=1327, 672)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Somnolence Post Dose 1 (N=1408, 703)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="635"/>
                    <measurement group_id="O2" value="375" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe Somnolence Post Dose 1 (N=1408, 703)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="26" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Somnolence Post Dose 2 (N=1348, 681)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="405"/>
                    <measurement group_id="O2" value="247" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe Somnolence Post Dose 2 (N=1348, 681)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="12" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Somnolence Post Dose 3 (N=1327, 672)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="272"/>
                    <measurement group_id="O2" value="204" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe Somnolence Post Dose 3 (N=1327, 672)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="11" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Anorexia Post Dose 1 (N=1408, 703)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="388"/>
                    <measurement group_id="O2" value="278" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe Anorexia Post Dose 1 (N=1408, 703)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="14" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Anorexia Post Dose 2 (N=1348, 681)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="327"/>
                    <measurement group_id="O2" value="195" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe Anorexia Post Dose 2 (N=1348, 681)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="11" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Anorexia Post Dose 3 (N=1327, 672)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="294"/>
                    <measurement group_id="O2" value="189" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe Anorexia Post Dose 3 (N=1327, 672)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="17" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Irritability Post Dose 1 (N=1408, 703)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="945"/>
                    <measurement group_id="O2" value="576" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe Irritability Post Dose 1 (N=1408, 703)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="47" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Irritability Post Dose 2 (N=1348, 681)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="799"/>
                    <measurement group_id="O2" value="492" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe Irritability Post Dose 2 (N=1348, 681)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="25" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Irritability Post Dose 3 (N=1327, 672)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="546"/>
                    <measurement group_id="O2" value="416" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe Irritability Post Dose 3 (N=1327, 672)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="17" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected from the day of the first injection (Day 0) through 6 months after the last injection.</time_frame>
      <desc>Total number of participants in each group adjusted for the participant that got a vaccine assigned for the other group. The number at risk for the solicited injection site and systemic reactions also reflects numbers with data.</desc>
      <group_list>
        <group group_id="E1">
          <title>DTaP-IPV-Hep B-PRP~T</title>
          <description>Participants received Diphtheria (D), tetanus (T), pertussis (acellular, component) (aP), hepatitis B (hep B [recombinant DNA]) and poliomyelitis (Inactivated [IPV]), and Haemophilus influenzae type b (Hib) conjugated vaccine adsorbed (DTaP-IPV-Hep B-PRP~T) plus a Placebo, oral poliovirus vaccine (OPV) in a 3-dose series with single doses at 2, 4, and 6 months of age.</description>
        </group>
        <group group_id="E2">
          <title>Tritanrix-Hep B/Hib™ + OPV</title>
          <description>Participants received Tritanrix-Hep B/Hib™ + oral poliovirus vaccine (OPV) in a 3-dose series with single doses at 2, 4, and 6 months of age.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 9.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="91" subjects_at_risk="1423"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="710"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardio Respiratory Distress</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="710"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Hip Dysplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="710"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Intussusception</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Gastric Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Inguinal Hernia, Obstructive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="710"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="710"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Choledochal Cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="710"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess Neck</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="1423"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="1423"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Encephalitis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="1423"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Kawasaki's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Laryngotracheitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Lymphangitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Periorbital Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1423"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1423"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Postoperative Wound Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Pyoderma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Pyoderma Streptococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="710"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Head Injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1423"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="710"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Encephalitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Febrile Convulsion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Hypotonic Hyporesponsive Episode</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Subarachnoid Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="710"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchial Hyperactivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Bronchial Obstruction</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="1423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Foreign Body Aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1423"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="710"/>
              </event>
              <event>
                <sub_title>Obstructive Airways Disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="710"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Purpura</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1423"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="710"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5.00</frequency_threshold>
        <default_vocab>MedDRA 9.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="945" subjects_at_risk="1423"/>
                <counts group_id="E2" subjects_affected="576" subjects_at_risk="710"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="131" subjects_affected="131" subjects_at_risk="1411"/>
                <counts group_id="E2" events="70" subjects_affected="70" subjects_at_risk="703"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="264" subjects_affected="264" subjects_at_risk="1411"/>
                <counts group_id="E2" events="123" subjects_affected="123" subjects_at_risk="703"/>
              </event>
              <event>
                <sub_title>Solicited Vomiting Post-dose 1</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="230" subjects_affected="230" subjects_at_risk="1410"/>
                <counts group_id="E2" events="120" subjects_affected="120" subjects_at_risk="703"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Solicited Injection site Erythema Post-dose 3</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="587" subjects_affected="587" subjects_at_risk="1410"/>
                <counts group_id="E2" events="340" subjects_affected="340" subjects_at_risk="703"/>
              </event>
              <event>
                <sub_title>Injection Site Haemorrhage</sub_title>
                <counts group_id="E1" events="39" subjects_affected="39" subjects_at_risk="1411"/>
                <counts group_id="E2" events="63" subjects_affected="63" subjects_at_risk="703"/>
              </event>
              <event>
                <sub_title>Injection Site Nodule</sub_title>
                <counts group_id="E1" events="81" subjects_affected="81" subjects_at_risk="1411"/>
                <counts group_id="E2" events="79" subjects_affected="79" subjects_at_risk="703"/>
              </event>
              <event>
                <sub_title>Solicited Injection Site Pain Post-dose 1</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="831" subjects_affected="831" subjects_at_risk="1410"/>
                <counts group_id="E2" events="574" subjects_affected="574" subjects_at_risk="703"/>
              </event>
              <event>
                <sub_title>Solicited Injection Site Swelling Post-dose 3</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="400" subjects_affected="400" subjects_at_risk="1408"/>
                <counts group_id="E2" events="323" subjects_affected="323" subjects_at_risk="703"/>
              </event>
              <event>
                <sub_title>Solicited Irritability post-dose 1</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="945" subjects_affected="945" subjects_at_risk="1410"/>
                <counts group_id="E2" events="576" subjects_affected="576" subjects_at_risk="703"/>
              </event>
              <event>
                <sub_title>Solicited Pyrexia Post-dose 2</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="675" subjects_affected="675" subjects_at_risk="1411"/>
                <counts group_id="E2" events="457" subjects_affected="457" subjects_at_risk="703"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="101" subjects_affected="101" subjects_at_risk="1411"/>
                <counts group_id="E2" events="40" subjects_affected="40" subjects_at_risk="703"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="742" subjects_affected="742" subjects_at_risk="1411"/>
                <counts group_id="E2" events="353" subjects_affected="353" subjects_at_risk="703"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="395" subjects_affected="395" subjects_at_risk="1411"/>
                <counts group_id="E2" events="161" subjects_affected="161" subjects_at_risk="703"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="136" subjects_affected="136" subjects_at_risk="1411"/>
                <counts group_id="E2" events="56" subjects_affected="56" subjects_at_risk="703"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Solicited Anorexia Post-dose 1</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="388" subjects_affected="388" subjects_at_risk="1410"/>
                <counts group_id="E2" events="278" subjects_affected="278" subjects_at_risk="703"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Solicited Somnolence Post-dose 1</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="635" subjects_affected="635" subjects_at_risk="1410"/>
                <counts group_id="E2" events="375" subjects_affected="375" subjects_at_risk="703"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Solicited Crying Post-dose 1</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="800" subjects_affected="800" subjects_at_risk="1411"/>
                <counts group_id="E2" events="564" subjects_affected="564" subjects_at_risk="703"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="163" subjects_affected="163" subjects_at_risk="1411"/>
                <counts group_id="E2" events="74" subjects_affected="74" subjects_at_risk="703"/>
              </event>
              <event>
                <sub_title>Rhinitis Allergic</sub_title>
                <counts group_id="E1" events="75" subjects_affected="75" subjects_at_risk="1411"/>
                <counts group_id="E2" events="36" subjects_affected="36" subjects_at_risk="703"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis Diaper</sub_title>
                <counts group_id="E1" events="160" subjects_affected="160" subjects_at_risk="1411"/>
                <counts group_id="E2" events="54" subjects_affected="54" subjects_at_risk="703"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Sanofi Pasteur Inc.</organization>
      <email>RegistryContactUs@sanofipasteur.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

